Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | PTPRB | P23467 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | STS | P08842 | 5/20 | 0.42 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2063007 | 0.93 | EPHX2 (0.47) | EPHX2PTPRBPTPN11MEN1KMT2A | |
| SCHEMBL15732621 | 0.87 | EPHX2 (0.40) | EPHX2 | |
| SCHEMBL11904712 | 0.87 | PTPRB (0.45) | PTPRBPTPN11MEN1KMT2ASTS | |
| SCHEMBL311398 | 0.73 | EPHX2 (0.57) | EPHX2KMT2ASTSSFRP1PTPN2 | |
| SCHEMBL3397674 | 0.73 | PTPRB (0.48) | PTPRBPTPN11MEN1KMT2ASTS | |
| SCHEMBL22265776 | 0.72 | GPR119 (0.66) | EPHX2GPR119 | |
| SCHEMBL1471050 | 0.72 | PDK2 (0.55) | MEN1KMT2AGPR119 | |
| SCHEMBL21723196 | 0.71 | KMT2A (0.52) | EPHX2MEN1KMT2ASTSPTPN2 | |
| SCHEMBL2340961 | 0.71 | PTPRB (0.52) | PTPRBPTPN11MEN1KMT2ASTS | |
| SCHEMBL10159468 | 0.71 | MEN1 (0.62) | MEN1KMT2ASTSGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | EPHX2 4803/4885PTPRB 1534/4885PTPN11 973/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | EPHX2 4803/4885PTPRB 1534/4885PTPN11 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.